Protection of dopaminergic neurons in primary culture by lisuride

Journal of Neural Transmission

Volumn 109, Issue 2, 2002, Pages 157-169

  Gille, G ^a   Rausch, W D ^b   Hung, S T ^b   Moldzio, R ^b   Ngyuen, A ^b   Janetzky, B ^a   Engfer, A ^c   Reichmann, H ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c BAYER PHARMA AG   (Germany)

Author keywords

L DOPA; Lisuride; MPP+; Neuroprotection; Oxidative stress; Parkinson's disease

Indexed keywords

DOPAMINE; LEVODOPA; LISURIDE; PYRIDINIUM DERIVATIVE;

ANAEROBIC METABOLISM; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DRUG EFFECT; EMBRYO; INCUBATION TIME; MOUSE; NERVE CELL CULTURE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIPARKINSON AGENTS; CELLS, CULTURED; CYTOPROTECTION; DOPAMINE; LEVODOPA; LISURIDE; MESENCEPHALON; MICE; MICE, INBRED C57BL; NEURONS; OXIDATIVE STRESS;

EID: 0036189532     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020200011     Document Type: Article

References (46)

1. L-dopa cytotoxicity to PC-12 cells in culture is via its auto-oxidation
2. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
3. Dopamine neurotoxicity: Inhibition of mitochondrial respiration
4. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: Implications for Parkinson's disease
5. Biochemical and toxicological properties of the oxidative products of catecholamines
6. Lisuride prevents learning and memory impairment and attenuates the increase in extracellular dopamine induced by transient global cerebral ischemia in rats
7. Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo
8. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion
9. Monoamine oxidase and mitochondrial respiration
10. Biochemical and molecular aspects of human mitochondrial respiratory chain disorders
11. Astrocyte-enhanced neuronal survival is mediated by scavenging of extracellular reactive oxygen species
12. Adverse effects of levodopa in Parkinson's disease
13. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats
14. Pergolide scavenges both hydroxyl and nitric free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain
15. Lisuride pharmacology and treatment of Parkinson's disease
16. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones
17. Inhibition of catalase in mesencephalic cultures by L-DOPA and dopamine
18. Glial cells protect neurons against oxidative stress via transcriptional up-regulation of the glutathione synthesis
19. 3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures
20. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy
21. Initiation of L-DOPA therapy in parkinsonian patients should be delayed until the advanced stages of the disease
22. Levodopa toxicity in fetal rat midbrain neurons in culture: Modulation by ascorbic acid
23. Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms
24. +) in rat dissociated mesencephalic cultures
25. Chronic activation of the cyclic AMP signaling pathway promotes development and long-term survival of mesencephalic dopaminergic neurons
26. Toxicity of 1-methyl-4-phenylpyridinium for rat dopaminergic neurons in culture
27. +) is toxic to mesencephalic dopamine neurons in culture
28. Toxic and protective effects of L-DOPA on mesencephalic cell cultures
29. Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro
30. Scavenging effects of dopamine agonists on nitric oxide radicals
31. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro
32. L-dopa inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells
33. Toxic effects of L-DOPA on mesencephalic cell cultures: Protection with antioxidants
34. + and beta amyloid peptide
35. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: Comparison to other dopamine receptor agonists
36. Mechanisms of MPTP toxicity
37. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity
38. Antiparkinsonian therapies and brain mitochondrial complex I activity
39. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
40. Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motor fluctuations. Long-term study over 10 years in comparison with l-dopa monotherapy
41. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial
42. + and glutamate in the degeneration of nigral dopaminergic neurons
43. Mitochondrial complex I deficiency in Parkinson's disease
44. Long term role of pergolide as an adjunct therapy in Parkinson's disease: Influence on disability, blood pressure, weight and levodopa syndrome
45. 2 receptors
46. Effects of chronic activation of dopamine D-2 receptors in cultures of rat fetal dopaminergic neurons: Indications for alterations in functional activity